TTR and hepatocellular carcinoma: We found that adjuvant TACE could improve the prognosis (OS and TTR) of HCC patients with vascular invasion (Supplementary Figure S2b) and larger tumor (Supplementary Figure S2d), whereas there were no significant differences in patients with no vascular invasion (Supplementary Figure S2a), small tumor size (Supplementary Figure S2c) and single or multiple tumors (Supplementary Figures S2e and f).